169 related articles for article (PubMed ID: 36972293)
1. Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study.
Landis MN; Smith SR; Berstein G; Fetterly G; Ghosh P; Feng G; Pradhan V; Aggarwal S; Banfield C; Peeva E; Vincent MS; Beebe JS; Tarabar S
Br J Dermatol; 2023 Jul; 189(1):33-41. PubMed ID: 36972293
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study.
Landis MN; Arya M; Smith S; Draelos Z; Usdan L; Tarabar S; Pradhan V; Aggarwal S; Banfield C; Peeva E; Vincent MS; Sikirica V; Xenakis J; Beebe JS
Br J Dermatol; 2022 Dec; 187(6):878-887. PubMed ID: 35986699
[TBL] [Abstract][Full Text] [Related]
3. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.
Papp KA; Bissonnette R; Gooderham M; Feldman SR; Iversen L; Soung J; Draelos Z; Mamolo C; Purohit V; Wang C; Ports WC
BMC Dermatol; 2016 Oct; 16(1):15. PubMed ID: 27716172
[TBL] [Abstract][Full Text] [Related]
4. Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials.
Lebwohl M; Warren RB; Sofen H; Imafuku S; Paul C; Szepietowski JC; Spelman L; Passeron T; Vritzali E; Napoli A; Kisa RM; Buck A; Banerjee S; Thaçi D; Blauvelt A
Br J Dermatol; 2024 Apr; 190(5):668-679. PubMed ID: 38226713
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of the TYK2/JAK1 Inhibitor Brepocitinib for Active Psoriatic Arthritis: A Phase IIb Randomized Controlled Trial.
Mease P; Helliwell P; Silwinska-Stanczyk P; Miakisz M; Ostor A; Peeva E; Vincent MS; Sun Q; Sikirica V; Winnette R; Qiu R; Li G; Feng G; Beebe JS; Martin DA
Arthritis Rheumatol; 2023 Aug; 75(8):1370-1380. PubMed ID: 37194394
[TBL] [Abstract][Full Text] [Related]
6. Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.
Eichenfield LF; Gower RG; Xu J; Alam MS; Su JC; Myers DE; Sanders P; Vlahos B; Zang C; Lan J; Werth J
Am J Clin Dermatol; 2023 Jul; 24(4):623-635. PubMed ID: 37184828
[TBL] [Abstract][Full Text] [Related]
7. The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial.
Worm M; Thyssen JP; Schliemann S; Bauer A; Shi VY; Ehst B; Tillmann S; Korn S; Resen K; Agner T
Br J Dermatol; 2022 Jul; 187(1):42-51. PubMed ID: 35084738
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials.
Feldman SR; Matheson R; Bruce S; Grande K; Markowitz O; Kempers S; Brundage T; Wyres M;
Am J Clin Dermatol; 2012 Aug; 13(4):261-71. PubMed ID: 22587791
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials.
Lebwohl MG; Sugarman JL; Stein Gold L; Lin T; Israel R
J Drugs Dermatol; 2019 Oct; 18(10):1012-1018. PubMed ID: 31584780
[TBL] [Abstract][Full Text] [Related]
10. Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.
Lebwohl MG; Kircik LH; Moore AY; Stein Gold L; Draelos ZD; Gooderham MJ; Papp KA; Bagel J; Bhatia N; Del Rosso JQ; Ferris LK; Green LJ; Hebert AA; Jones T; Kempers SE; Pariser DM; Yamauchi PS; Zirwas M; Albrecht L; Devani AR; Lomaga M; Feng A; Snyder S; Burnett P; Higham RC; Berk DR
JAMA; 2022 Sep; 328(11):1073-1084. PubMed ID: 36125472
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.
Ports WC; Khan S; Lan S; Lamba M; Bolduc C; Bissonnette R; Papp K
Br J Dermatol; 2013 Jul; 169(1):137-45. PubMed ID: 23387374
[TBL] [Abstract][Full Text] [Related]
12. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.
Lebwohl MG; Stein Gold L; Strober B; Papp KA; Armstrong AW; Bagel J; Kircik L; Ehst B; Hong HC; Soung J; Fromowitz J; Guenthner S; Piscitelli SC; Rubenstein DS; Brown PM; Tallman AM; Bissonnette R
N Engl J Med; 2021 Dec; 385(24):2219-2229. PubMed ID: 34879448
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
[TBL] [Abstract][Full Text] [Related]
14. Trial of Roflumilast Cream for Chronic Plaque Psoriasis.
Lebwohl MG; Papp KA; Stein Gold L; Gooderham MJ; Kircik LH; Draelos ZD; Kempers SE; Zirwas M; Smith K; Osborne DW; Trotman ML; Navale L; Merritt C; Berk DR; Welgus H;
N Engl J Med; 2020 Jul; 383(3):229-239. PubMed ID: 32668113
[TBL] [Abstract][Full Text] [Related]
15. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial.
Rosmarin D; Pandya AG; Lebwohl M; Grimes P; Hamzavi I; Gottlieb AB; Butler K; Kuo F; Sun K; Ji T; Howell MD; Harris JE
Lancet; 2020 Jul; 396(10244):110-120. PubMed ID: 32653055
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial.
Guenther L; Van de Kerkhof PC; Snellman E; Kragballe K; Chu AC; Tegner E; Garcia-Diez A; Springborg J
Br J Dermatol; 2002 Aug; 147(2):316-23. PubMed ID: 12174105
[TBL] [Abstract][Full Text] [Related]
17. Antistreptococcal interventions for guttate and chronic plaque psoriasis.
Dupire G; Droitcourt C; Hughes C; Le Cleach L
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD011571. PubMed ID: 30835819
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study.
Cai L; Li L; Cheng H; Ding Y; Biao Z; Zhang S; Geng S; Liu Q; Fang H; Song Z; Lu Y; Li S; Guo Q; Tao J; He L; Gu J; Yang Q; Han X; Gao X; Deng D; Li S; Wang Q; Zhu J; Zhang J
Adv Ther; 2022 Jan; 39(1):583-597. PubMed ID: 34816373
[TBL] [Abstract][Full Text] [Related]
19. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
King B; Guttman-Yassky E; Peeva E; Banerjee A; Sinclair R; Pavel AB; Zhu L; Cox LA; Craiglow B; Chen L; Banfield C; Page K; Zhang W; Vincent MS
J Am Acad Dermatol; 2021 Aug; 85(2):379-387. PubMed ID: 33757798
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of PF-07038124 in Patients With Atopic Dermatitis and Plaque Psoriasis: A Randomized Clinical Trial.
Eichenfield LF; Tarabar S; Forman S; García-Bello A; Feng G; Fetterly G; Mahling P; Peeva E; Vincent MS; Chandra DE
JAMA Dermatol; 2024 Feb; 160(2):156-163. PubMed ID: 38117526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]